St. Vincent’s Riverside is now offering a breakthrough treatment for patients diagnosed with chronic pulmonary obstructive ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

The firm is commercializing and developing treatments for various diseases of the cornea. Its potential market size is rather small, but the company has little apparent direct competition and has ...

Most importantly, the presence of albuminuria increased the risk for restrictive lung disease (OR 8.57) as compared to non-diabetic patients (Figure 1B). Multidetector computed tomography confirmed ...

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the ...

Comprehensive approaches including large-scale screening and targeted treatments are essential to reduce lung cancer mortality.

Rationale Pulmonary tuberculosis (PTB) can cause post-TB lung disease (PTLD ... We tested the differences in the burden of disease using symptom scores, spirometry and 6 min walk test at TB-treatment ...

Background Patients with interstitial lung disease (ILD) are at risk of developing nocturnal hypoxaemia due to ventilatory restriction and impaired gas exchange that worsen with supine posture and ...

The purpose of this meta-analysis was to find additional RTTTs since our 2018 meta-analysis that enrolled subjects with CVD hospitalized for ACS or noncardiac indications comparing liberal versus ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...

reduce disease burden, and decrease the need for whole lung lavage (WLL), a current treatment for aPAP. According to InvestingPro data, the company maintains a strong financial position with more cash ...